Search results for " biologics"
Article
Challenges of Protein Aggregation During Purification
Focus on avoidance
Recently, there has been significant effort to prevent aggregation by carefully selecting and/or designing active biologics that are more resistant to aggregation and/or cell li…
Article
Q&A with Industry Leaders: Rita Peters
This trend continued at Interphex 2014 with the introduction of equipment and systems targeting biologics manufacturing.
In other developments, mergers, acquisitions, and supplier consolidation co…
Article
HT Multi-Product Liquid Chromatography for Characterization of Monoclonal Antibodies
If used correctly, these new analytical methods can reduce analysis and product development time.
ABSTRACT
Monoclonal antibodies represent a significant portion of sales in the biopharma…
Article
Advancing QbD in the EU
EU authorities are stepping up their efforts to incorporate QbD principles.
The European Commission (EC) and the European Medicines Agency (EMA), have been supporting quality-by-design (QbD)…
Article
The Future of Biopharma
Many are relying on suppliers' innovations to advance production processes for current biologics, emerging biosimilars products, and for the production of biologics in emerging markets using flexible …
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Newer classes of biotherapies will require innovations in processing technology.
By Glen R. Bolton, Bernard N. Violand, Richard S. Wright, Shujun Sun, Khurram M. Sunasara, Kathleen Watson, Johna…
Article
Pushing the Barriers in Next-Gen Antibody Development
Continued development of new and next-generation antibodies is spurred by the increasing demand for more effective and custom-tailored biologic therapies. In particular, bispecific antibodi…
Article
Genetic Vaccine Platforms Demonstrate Their Potential
In a pandemic, genetic vaccines offer several advantages over traditional approaches.
By Cynthia A. Challener
For a vaccine to be effective, the components of the disease o…
Article
Manage HCPs and Enhance Your Route to Market
Click here to read more >>
Host cell protein (HCP) management is critical to biologics development—and getting it wrong could delay your development cycle. Learn how the right HCP strategy can e…
Article
Biomanufacturing: Demand for Continuous Bioprocessing Increasing
Some of these technologies also support the increasing demand for biologics that may be called for in smaller quantities.
Figure 2 shows the economic commitment decision-makers are focusing on …